Brief: Xilio Therapeutics Announces Initiation Of Enrollment For Phase 1 Combination Trial Of XTX101
07/12/2023 12:36
Dec 7 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES INITIATION OF ENROLLMENT FOR
PHASE
1 COMBINATION TRIAL OF XTX101, A TUMOR-ACTIVATED, FC-ENHANCED
ANTI-CTLA-4, AND UPDATED PHASE 1 MONOTHERAPY DATA
* XILIO THERAPEUTICS - PHASE 1 COMBINATION DOSE ESCALATION
EXPECTED TO SUPPORT PLANNED PHASE 2 TRIAL IN MICROSATELLITE
STABLE COLORECTAL CANCER (MSS CRC)
* XILIO THERAPEUTICS INC - SAFETY DATA WERE CONSISTENT WITH
PREVIOUSLY REPORTED RESULTS
Source text for Eikon: ID:nGNX5SyLlX
Further company coverage: XLO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla